Cyclosporin a promotes tumor angiogenesis in a calcineurin-independent manner by increasing mitochondrial reactive oxygen species

Molecular Cancer Research

Volumn 12, Issue 11, 2014, Pages 1663-1676

  Zhou, Alice Yao ^a   Ryeom, Sandra ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CALCINEURIN; CYCLOSPORIN A; REACTIVE OXYGEN METABOLITE; CYCLOSPORIN; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; APOPTOSIS ASSAY; ARTICLE; CANCER RISK; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; SKIN CARCINOGENESIS; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; C57BL MOUSE; CELL MOTION; DRUG EFFECTS; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION; SKIN TUMOR; VASCULARIZATION;

ANIMALS; ANTIOXIDANTS; CALCINEURIN; CELL MOVEMENT; CELL PROLIFERATION; CYCLOSPORINE; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE, INBRED C57BL; MITOCHONDRIA; NEOVASCULARIZATION, PATHOLOGIC; REACTIVE OXYGEN SPECIES; SKIN NEOPLASMS;

EID: 84910656628     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0136     Document Type: Article

References (50)

1. Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW. Posttransplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int 2006;19:607-20.
2. Rusnak F, Mertz P. Calcineurin: form and function. Physiol Rev 2000; 80:1483-521.
3. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91.
4. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. Lancet 1995;346:403-6.
5. Harwood CA, Surentheran T, McGregor JM, Spink PJ, Leigh IM, Breuer J, Proby C. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000;61:289-297
6. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-Autonomous mechanism. Nature 1999;397:530-4.
7. Kuschal C, Thoms K-M, Boeckmann L, Laspe P, Apel A, Schön MP, et al. Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group A and G proteins, which is mediated by calcineurin inhibition. Exp Dermatol 2011;20: 795-9.
8. Norman KG, Canter J a, Shi M, Milne GL, Morrow JD, Sligh JE. Cyclosporine A suppresses keratinocyte cell death through MPTP inhibition in a model for skin cancer in organ transplant recipients. Mitochondrion 2010;10:94-101.
9. Wu X, Nguyen B-C, Dziunycz P, Chang S, Brooks Y, Lefort K, et al. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 2010;465:368-72.
10. Baek K-H, Zaslavsky A, Lynch RC, Britt C, Okada Y, Siarey RJ, et al. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 2009;459:1126-30.
11. Hesser BA, Liang XH, Camenisch G, Yang S, Lewin DA, Scheller R, et al. Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood 2004;104:149-58.
12. Iizuka M, Abe M, Shiiba K, Sasaki I, Sato Y. Down syndrome candidate region 1, a downstream target of VEGF, participates in endothelial cell migration and angiogenesis. J Vasc Res 2004;41:334-44.
13. Minami T, Yano K, Miura M, Kobayashi M, Suehiro J, Reid PC, et al. The Down syndrome critical region gene 1 short variant promoters direct vascular bed-specific gene expression during inflammation in mice. J Clin Invest 2009;119:2250-70.
14. Shin J, Lee J, Baek K-H. A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis. Cancer Lett 2013;1:1-12.
15. Yao Y-G, Duh EJ. VEGF selectively induces Down syndrome critical region 1 gene expression in endothelial cells: a mechanism for feedback regulation of angiogenesis? Biochem Biophys Res Commun 2004;321:648-56.
16. Wang P, Heitman J. The cyclophilins. Genome Biol 2005;6:226.
17. Lee J, Kim SS. Current implications of cyclophilins in human cancers. J Exp Clin Cancer Res 2010;29:97.
18. Nakagawa T, Shimizu S, Watanabe T. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005;434:652-8.
19. Waldmeier PC, Feldtrauer J-J, Qian T, Lemasters JJ. Inhibition of the mitochondrial permeability transition by the nonimmunosuppressive cyclosporin derivative NIM811. Mol Pharmacol 2002;62: 22-9.
20. Zhang DX, Gutterman DD. Mitochondrial reactive oxygen speciesmediated signaling in endothelial cells. AmJ Physiol Heart Circ Physiol 2007;292:2023-31.
21. Moldovan L, Mythreye K, Goldschmidt-Clermont PJ, Satterwhite LL. Reactive oxygen species in vascular endothelial cell motility. Roles of NAD(P)H oxidase and Rac1. Cardiovasc Res 2006;71:236-46.
22. Weinberg F, Hamanaka R, WheatonWW,Weinberg S, Joseph J, Lopez M, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 2010;107: 8788-93.
23. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 2005;1:401-8.
24. Neilson JR, Winslow MM, Hur EM, Crabtree GR. Calcineurin B1 is essential for positive but not negative selection during thymocyte development. Immunity 2004;20:255-66.
25. Skuli N, Majmundar AJ, Krock BL, Mesquita RC, Mathew LK, Quinn ZL, et al. Endothelial HIF-2 a regulates murine pathological angiogenesis and revascularization processes. J Clin Invest 2012;122:1427-43.
26. Reddy K, Zhou Z, Schadler K, Jia S-F, Kleinerman ES. Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing's tumor vessels. Mol Cancer Res 2008;6:929-36.
27. Ryeom S, Baek K-H, Rioth MJ, Lynch RC, Zaslavsky A, Birsner A, et al. Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. Cancer Cell 2008;13:420-31.
28. Yajima Y, Sueki H, Oguro T, Yoshida T, Iijima M. Effects of oral administration of ciclosporin A on skin carcinogenesis: a study using the two-stage carcinogenesis protocol in mice. Clin Exp Dermatol 2008;33:478-83.
29. Rosenwirth BE, Billich A, Datema R, Donatsch P, Hammerschmid F, Harrison R, et al. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob Agents Chemother 1994;38:1763-72.
30. Giorgio V, Soriano ME, Basso E, Bisetto E, Lippe G, Forte MA, et al. CyclophilinDin mitochondrial pathophysiology. Biochim Biophys Acta 2010;1797:1113-8.
31. Malouitre S, Dube H, Selwood D, Crompton M. Mitochondrial targeting of cyclosporin A enables selective inhibition of cyclophilin-D and enhanced cytoprotection after glucose and oxygen deprivation. Biochem J 2010;425:137-48.
32. Sullivan PG, Thompson MB, Scheff SW. Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury. Exp Neurol 1999;160:226-34.
33. Redondo-Horcajo M, Romero N, Martínez-Acedo P, Martínez-Ruiz A, Quijano C, Loureņco CF, et al. Cyclosporine A-induced nitration of tyrosine 34 MnSOD in endothelial cells: role of mitochondrial superoxide. Cardiovasc Res 2010;87:356-65.
34. Akool E-S, Gauer S, Osman B, Doller A, Schulz S, Geiger H, et al. Cyclosporin A and tacrolimus induce renal Erk1/2 pathway via ROSinduced and metalloproteinase-dependent EGF-receptor signaling. Biochem Pharmacol 2012;83:286-95.
35. Wang X, Jian C, Zhang X, Huang Z, Xu J, Hou T, et al. Superoxide flashes: elemental events of mitochondrial ROS signaling in the heart. J Mol Cell Cardiol 2012;52:940-8.
36. Jiang B, Hebert VY, Li Y, Mathis JM, Alexander JS, Dugas TR. HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. Toxicol Appl Pharmacol 2007;224:60-71.
37. Ferro E, Goitre L, Retta SF, Trabalzini L. The Interplay between ROS and Ras GTPases: physiological and pathological implications. J Signal Transduct 2012;2012:3657-69.
38. Meng T-C, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 2002;9:387-99.
39. Basu A, Contreras AG, Datta D, Flynn E, Zeng L, et al. Overexpression of vascular endothelial growth factor and the development of posttransplantation cancer. Cancer Res 2008;68:5689-98.
40. Banerjee P, Basu A, Wegiel B, Otterbein LE, Mizumura K, et al. Heme oxygenase-1 promotes survivial of renal cancer cells through modulation of apoptosis-And autophagy-regulating molecules. J Biol Chem 2012;287:32113-23.
41. Banerjee P, Basu A, Arbiser JL, Pal S. The natural product honokiol inhibits calcineurin-inhibitor-induced and Ras-mediated tumor promoting pathways. Cancer Letters 2013;338:292-299.
42. Alvarez-Arroyo MV, Yague S, Wenger RM, Pereira DS, Jimenez S, Caramelo C, et al. Cyclophilin-mediated pathways in the effect of cyclosporin A on endothelial cells: role of vascular endothelial growth factor. Circulation Res 2002;91:202-209
43. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-95.
44. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17:1359-70.
45. Gollogly LK, Ryeom SW, Yoon SS. Down syndrome candidate region 1-like 1 (DSCR1-L1) mimics the inhibitory effects of DSCR1 on calcineurin signaling in endothelial cells and inhibit angiogenesis. J Surg Res 2007;142:129-36.
46. Nguyen AHT, B-eland M, Gaitan Y, Bouchard M. Calcineurin a-binding protein, a novelmodulator of the calcineurin-nuclear factor of activated T-cell signaling pathway, is overexpressed in Wilms' tumors and promotes cell migration. Mol Cancer Res 2009;7:821-31.
47. Ichas F, Mazat JP. From calcium signaling to cell death: two conformations for the mitochondrial permeability transition pore. Switching from low-to high-conductance state. Biochim Biophys Acta 1998;1366:33-50.
48. Huser J, Blatter L. Fluctuations in mitochondrial membrane potential caused by repetitive gating of the permeability transition pore. Biochem Soc 1999;317:311-7.
49. Korshunov SS, Skulachev VP, Starkov AA. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett 1997;416:15-8.
50. Finkel T. Signal transduction by reactive oxygen species. J Cell Biol 2011;194:7-15.